BioMimetic Therapeutics, Inc. (BMTI) Posts Wider than Expected Q4 Loss
Tweet
Share
E-mailGet Alerts BMTI Hot Sheet
Price: $9.49 --0%
Financial Fact:
Loss before income taxes: -4.6M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Loss before income taxes: -4.6M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) reported Q4 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $458 thousand versus the consensus estimate of $310 thousand.
For earnings history and earnings-related data on BioMimetic Therapeutics, Inc. (BMTI) click here.
For earnings history and earnings-related data on BioMimetic Therapeutics, Inc. (BMTI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
- Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
